Related Articles
Lisocabtagene maraleucel as a second-line treatment for R/R LBCL: PROs from the PILOT study
Here, we summarize a health-related quality of life and patient-reported outcomes analysis from the phase II PILOT trial, published by Gordon et al. in Haematologica.
Correlation between MRD at the end of induction and EFS in pediatric T-cell lymphoblastic lymphoma
Here, we summarize a subgroup analysis of the Children’s Oncology Group AALL1231 trial investigating the correlation between MRD at the end of induction and event-free…
Waldenström’s macroglobulinemia | Lymphoma Hub
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease
STARGLO trial of glofitamab: primary endpoint met in R/R DLBCL
Results obtained from the phase III STARGLO trial showed that glofitamab met its primary endpoint of overall response in patients with R/R DLBCL who received…
What are the strategies to manage toxicities with CAR T-cell therapies?
During the 6th European CAR T-Cell Meeting, the Lymphoma Hub was pleased to speak to the president of EBMT, Anna Sureda, Catalan Institute of Oncology,…
Venetoclax monotherapy for patients with R/R CLL: Results from the phase III VENICE-1 trial
Here we summarize the results from the VENICE-1 trial evaluating venetoclax monotherapy in patients with R/R CLL, published by Kater et al.1 in Lancet Oncology.
SYMPATICO: Is ibrutinib combined with venetoclax safe and effective in patients with R/R MCL?
During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Michael Wang, MD Anderson Cancer Center, Houston, US.…
Polatuzumab vedotin in combination with venetoclax and rituximab for patients with R/R DLBCL
Here, we summarize results from a phase Ib/II trial assessing the safety and efficacy of polatuzumab vedotin in combination with rituximab and lenalidomide in patients…
GLOW trial: A 4-year update on fixed-duration ibrutinib + venetoclax in previously untreated CLL
Here, we summarize the 4-year follow-up data from the phase III GLOW trial investigating fixed duration ibrutinib + venetoclax vs chlorambucil + obinutuzumab in previously…
TARMAC trial: Time-limited ibrutinib plus CAR T-cell therapy for the treatment of R/R MCL
Here, we summarize the results of the phase II TARMAC trial, published by Minson et al.1 in Blood, of the combination of time-limited ibrutinib and…